cingulate therapeutics logo

Cingulate Therapeutics

Cingulate Therapeutics (CTx) is a privately held biopharma company developing new products for the treatment of Neurobiological Disorders. Currently, CTx is developing two products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://cingulatetherapeutics.com
Founded2012
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1901 Olathe Blvd, Missouri 66103
Kansas City,
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cingulate-therapeutics” connections=”true” suffix=””]

Sep 2014, Catalent Pharma Solutions signed an exclusive development and licensing agreement with Cingulate Therapeutics, to support the development of a series of new prescription pharmaceutical products for the treatment of ADHD using Catalents OSDrC OptiDose drug delivery platform.

In July 2018, Cingulate Therapeutics LLC announced a $7.5Mn equity investment from Werth Family Investment Associates. The capital will advance lead products into further clinical trials.